Texas Institute of Cardiology, PA
Texas Institute of Cardiology, PA
McKinney, Texas, United States7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Arterial Occlusive Diseases, Body Weight, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, kidney disorder, kidney failure, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07783802 | |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-10-07 | NCT05556512 | |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07157774 | |
| A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-05-29 | NCT06952530 | |
| A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, hypertensive disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Active, not recruiting | Phase 3 | 2026-05-29 | NCT06948435 | |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-05-29 | NCT06948422 |